Astrana Health, Inc. ASTH R2K
Company Overview
Astrana Health, Inc., a healthcare management company, provides medical care services in the United States. The company operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. Its physician network includes primary care physicians, specialist physicians and extenders, and hospitalists. The company serves patients primarily covered by private or public insurance, such as Medicare, Medicaid, and health maintenance organization; and non-insured patients. The company was formerly known as Apollo Medical Holdings, Inc. and changed its name to Astrana Health, Inc. in February 2024. Astrana Health, Inc. was founded in 1992 and is headquartered in Alhambra, California.
Why Investors Should Care
Revenue has grown at a 56.4% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $3.18B (+56.4% YoY); net profit $22.49M.
- Trailing 12 Months Year-on-year growth — revenue +55.6%, earnings +110.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 56.4%, profit CAGR 9.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 56.36% |
| 1 Year: | 55.60% |
Compounded Profit Growth
| 5 Years: | 9.76% |
| 1 Year: | 110.10% |
Stock Price Performance
| 1 Year: | +95.06% |
| 6 Months: | +72.35% |
| 3 Months: | +69.67% |
| 1 Month: | +22.96% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)72.78 · Overbought
P/E of 80.33 is above the sector median of 25.41 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 56.4% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 80.3.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ASTH Astrana Health, Inc. R2K | 49.00 | 80.33 | $2.43B | 0.00% | 4.90% | 5.66% | 56.36% | 9.76% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2014 | Sep 2014 | Dec 2014 | Jun 2015 | Sep 2015 | Dec 2015 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 122.67M | 166.73M | 95.76M | 130.05M | 156.06M | 178.75M | 165.10M | 165.17M | 180.12M | 176.78M | 176.06M | 175.64M | 227.12M | 263.26M | 269.70M | 317.00M | 337.24M | 348.21M | 348.17M | 404.36M | 486.26M | 478.71M | 620.39M | 654.81M | 956.05M | 950.53M | 965.10M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 549.06M | 576.84M | 858.86M | 855.48M | 859.36M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 71.33M | 77.97M | 97.19M | 95.04M | 105.74M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 50.75M | 57.63M | 77.98M | 76.65M | 77.22M |
| Operating Income | -1.19M | 1.86M | -1.53M | -1.66M | -412.91K | -1.46M | -1.76M | -2.17M | -1.68M | 15.68M | 4.06M | 21.25M | 22.70M | 7.15M | 56.58M | -3.31M | 14.73M | 10.07M | 10.93M | 4.37M | 12.91M | 37.36M | 25.88M | 21.78M | 20.99M | 53.16M | 26.21M | 15.38M | 50.09M | 22.37M | 27.03M | 39.08M | 30.14M | 30.07M | 28.43M | 20.58M | 20.34M | 19.21M | 18.39M | 28.53M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 23.76M | 31.11M | 38.98M | 41.43M | 51.29M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.31M | 7.38M | 17.72M | 17.52M | 16.10M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.60M | 16.82M | 5.67M | 7.51M | 19.71M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.38M | 6.61M | 4.59M | 944.00K | 6.58M |
| Net Income | -1.68M | 1.38M | -1.69M | -2.48M | -531.37K | -1.69M | -1.32M | -1.36M | -1.73M | 4.35M | 1.99M | 5.62M | 2.16M | 2.66M | 9.11M | 140.00K | 3.54M | 3.70M | 6.73M | 4.05M | 7.04M | 16.71M | 10.06M | 13.15M | 12.66M | 34.28M | 14.26M | 11.95M | 23.18M | 13.13M | 13.17M | 22.06M | 14.84M | 19.17M | 16.09M | 6.69M | 9.42M | 373.00K | 6.00M | 14.44M |
| Diluted EPS | - | 0.26 | -0.35 | - | -0.11 | -0.31 | - | - | - | 0.15 | 0.07 | 0.20 | 0.06 | 0.07 | 0.24 | 0.00 | 0.09 | 0.10 | 0.18 | 0.11 | 0.19 | 0.45 | 0.26 | 0.30 | 0.28 | 0.74 | 0.31 | 0.26 | 0.50 | 0.28 | 0.28 | 0.47 | 0.31 | 0.40 | 0.33 | 0.14 | 0.19 | 0.01 | 0.12 | 0.29 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jan 2011 | Jan 2012 | Jan 2013 | Jan 2014 | Mar 2015 | Mar 2016 | Dec 2016 | Mar 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.90M | 5.11M | 7.78M | 10.48M | 32.99M | 44.05M | 305.93M | 57.43M | 356.36M | 519.91M | 560.62M | 687.18M | - | 1.14B | 1.39B | 2.03B | 3.18B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 944.68M | 1.17B | 1.76B | 2.84B |
| Gross Profit | 581.86K | 978.41K | 1.46M | 1.41M | - | - | - | - | - | - | - | - | - | 199.48M | 214.96M | 271.39M | 341.53M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 95.21M | 130.34M | 182.04M | 263.00M |
| Operating Income | 4.01K | -413.33K | -2.08M | -3.91M | -694.33K | -7.27M | 11.69M | -10.54M | 35.15M | 88.43M | 32.42M | 80.50M | - | 104.27M | 84.61M | 89.35M | 78.53M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | 112.08M | 123.69M | 141.84M | 135.28M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.92M | 16.10M | 33.10M | 49.93M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | 86.62M | 89.84M | 80.82M | 39.61M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 40.88M | 31.99M | 30.89M | 15.53M |
| Net Income | -156.33K | -720.35K | -8.90M | -5.02M | -1.80M | -9.34M | 11.45M | -8.97M | 25.80M | 10.84M | 14.12M | 37.87M | - | 45.17M | 60.72M | 43.15M | 22.49M |
| Diluted EPS | - | - | - | - | - | - | 0.41 | - | 0.90 | 0.29 | 0.39 | 1.01 | - | 1.08 | 1.29 | 0.90 | 0.46 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jan 2010 | Jan 2011 | Jan 2012 | Jan 2013 | Jan 2014 | Mar 2014 | Mar 2015 | Dec 2015 | Mar 2016 | Dec 2016 | Mar 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 1.26M | 1.36M | 3.22M | 3.96M | 9.48M | 15.00M | - | 19.57M | 350.00M | 20.64M | 490.64M | 513.00M | 728.71M | 817.49M | - | 966.21M | 933.36M | 1.35B | 2.22B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 428.12M | 461.51M | 638.50M | 863.31M |
| Cash & Equivalents | 665.74K | 397.10K | 164.36K | 1.18M | 1.45M | 6.83M | 5.01M | 59.01M | 9.27M | 54.82M | 8.66M | 99.75M | 106.89M | 103.19M | 193.47M | - | 288.03M | 293.81M | 288.45M | 429.47M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 49.63M | 76.78M | 275.99M | 374.46M |
| Total Liabilities | - | 1.34M | 1.79M | 3.61M | 5.65M | 11.11M | 15.99M | - | 11.02M | 99.56M | 20.37M | 154.32M | 106.34M | 367.65M | 372.34M | - | 407.67M | 522.59M | 840.73M | 1.66B |
| Current Liabilities | - | 92.75K | 1.52M | 1.70M | 4.55M | 2.32M | 5.97M | - | 7.43M | 50.63M | 14.54M | 109.60M | 72.02M | 105.42M | 114.99M | - | 148.61M | 218.67M | 365.61M | 615.27M |
| Long Term Debt | - | - | - | - | - | - | 10.72M | - | - | - | - | - | 0 | 232.17M | 230.21M | - | 203.39M | 258.94M | 425.30M | 990.90M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 229.36M | 321.01M | 470.68M | 1.08B |
| Total Equity | -46.39K | -311.31K | -659.32K | -354.88K | -2.62M | -2.41M | -2.82M | 84.50M | -1.27M | 87.21M | -353.88K | 159.95M | 180.55M | 191.55M | 330.82M | - | 542.56M | 614.22M | 712.72M | 779.29M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 56.87M | 57.43M | 58.53M | 59.46M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jan 2011 | Jan 2012 | Jan 2013 | Jan 2014 | Mar 2015 | Mar 2016 | Dec 2016 | Mar 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -245.03K | -385.45K | 57.96K | -1.48M | - | - | 21.91M | - | 51.83M | 25.50M | 13.67M | 46.16M | - | 82.13M | 68.23M | 52.20M | 114.60M |
| Investing Cash Flow | -21.16K | 157.00K | -31.68K | -272.93K | - | - | -8.96M | - | 26.72M | -25.18M | -180.63M | 95.49M | - | -7.11M | -65.52M | -192.40M | -539.00M |
| Financing Cash Flow | -2.44K | -4.29K | 986.10K | 2.03M | - | - | -17.15M | - | -14.98M | -11.18M | 163.33M | -51.70M | - | -20.09M | 3.42M | 135.15M | 569.35M |
| Capital Expenditure | -21.16K | -7.21K | -45.80K | -22.93K | -44.51K | -262.11K | -3.31M | -297.56K | -2.08M | -1.17M | -1.04M | -1.16M | - | -22.94M | -28.53M | -8.03M | -10.11M |
| Free Cash Flow | -266.20K | -392.66K | 12.16K | -1.50M | - | - | 18.61M | - | 49.75M | 24.33M | 12.63M | 45.00M | - | 59.19M | 39.70M | 44.17M | 104.49M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | 54.93M | 6.12M | -5.05M | 144.94M |
| Share Buybacks | - | - | - | 0 | 500 | - | 517.50K | - | 3.18M | 5.05M | 7.57M | 537.00K | 5.74M | 9.25M | 10.19M | 900.00K | 25.60M |
| Dividends Paid | - | - | - | - | - | - | 26.66M | - | 10.45M | 17.76M | 61.72M | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Jan 2011 | Jan 2012 | Jan 2013 | Jan 2014 | Mar 2015 | Mar 2016 | Dec 2016 | Mar 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 14.9% | 19.1% | 18.8% | 13.4% | - | - | - | - | - | - | - | - | - | 17.4% | 15.5% | 13.3% | 10.7% |
| Operating Margin % | 0.1% | -8.1% | -26.7% | -37.3% | -2.1% | -16.5% | 3.8% | -18.3% | 9.9% | 17.0% | 5.8% | 11.7% | - | 9.1% | 6.1% | 4.4% | 2.5% |
| Net Margin % | -4.0% | -14.1% | -114.5% | -47.9% | -5.5% | -21.2% | 3.7% | -15.6% | 7.2% | 2.1% | 2.5% | 5.5% | - | 3.9% | 4.4% | 2.1% | 0.7% |
| ROE % | 50.2% | 109.3% | 2,509.2% | 191.7% | 64.0% | 736.1% | 13.1% | 2,534.7% | 16.1% | 6.0% | 7.4% | 11.4% | - | 8.3% | 9.9% | 6.1% | 2.9% |
| ROCE % | 0.3% | 273.3% | -136.9% | 660.2% | -7.7% | -59.9% | 3.9% | -172.7% | 9.2% | 20.1% | 5.2% | 11.5% | - | 12.8% | 11.8% | 9.0% | 4.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 17.22% | 6.16M | $302.27M |
| 2 | Vanguard Portfolio Management LLC | 6.36% | 2.28M | $111.65M |
| 3 | 325 Capital Llc | 5.14% | 1.84M | $90.19M |
| 4 | Vanguard Capital Management LLC | 4.78% | 1.71M | $83.87M |
| 5 | State Street Corporation | 4.61% | 1.65M | $80.94M |
| 6 | Dimensional Fund Advisors LP | 3.82% | 1.37M | $67.09M |
| 7 | Wellington Management Group, LLP | 3.75% | 1.34M | $65.80M |
| 8 | Geode Capital Management, LLC | 2.90% | 1.04M | $50.91M |
| 9 | 683 Capital Management LLC | 1.96% | 700.00K | $34.33M |
| 10 | Charles Schwab Investment Management, Inc. | 1.80% | 644.17K | $31.59M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ASTH
Astrana Health, Inc. Schedules 2026 Second Quarter Financial Results Release and Conference Call
Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a physician-centric, technology-enabled healthcare company empowering providers to deliver accessible, high-quality,…
Astrana Health Strengthens Leadership Team to Accelerate Long-Term Growth
Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a physician-centric, technology-enabled healthcare company empowering providers to deliver accessible, high-quality,…
Astrana Health ACOs Deliver $120.4 Million in Gross Shared Savings in 2024 Performance Year
Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a physician-centric, technology-enabled healthcare company empowering providers to deliver accessible, high-quality,…
1 Profitable Stock to Target This Week and 2 We Question
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Astrana Health, Inc. (ASTH) Surges 7.3%: Is This an Indication of Further Gains?
Astrana Health, Inc. (ASTH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.…
2 Healthcare Stocks for Long-Term Investors and 1 We Turn Down
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 12.9% over the past six months, topping the S&P 50…
ASTH — Frequently Asked Questions
What is the current share price of Astrana Health, Inc. (ASTH)?
As of 2026-07-14 21:23 PDT, Astrana Health, Inc. (ASTH) trades at $49.00 on NasdaqCM. Its 52-week range is $18.16 to $49.81.
What is the market capitalisation of ASTH?
Astrana Health, Inc. (ASTH) has a market capitalisation of $2.43B on NasdaqCM.
What is the P/E ratio of ASTH?
ASTH trades at a trailing price-to-earnings (P/E) ratio of 80.33. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 2.36.
What is the return on equity (ROE) of ASTH?
ASTH has a return on equity (ROE) of 5.66%. Its return on capital employed (ROCE) is 4.90%.
Is ASTH a good stock to buy?
This page provides a data-driven analysis of Astrana Health, Inc. (ASTH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.